Search

Displaying results 2081 - 2090 of 4588 in total
  1. Drug

    Ethylmorphine

    go.drugbank.com/drugs/DB01466
    IllicitInvestigational

    It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world.

  2. Drug

    Copanlisib

    go.drugbank.com/drugs/DB12483
    ApprovedInvestigational

    [A261730] Copanlisib was granted accelerated approval by the FDA in September 2017 for the treatment of follicular lymphoma.[A261725]

  3. Drug

    Balsam of Peru

    go.drugbank.com/drugs/DB11482
    ApprovedNutraceuticalVet approved

    [L2879] By Health Canada, the balsam of Peru is approved by the use of over-the-counter combination products and it is currently approved in veterinary products. … It is constituted by a mixture of substances from which the major components are benzyl cinnamate and [DB00676].

  4. Drug

    Succinylcholine

    go.drugbank.com/drugs/DB00202
    ApprovedInvestigational

    Succinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter [acetylcholine] (ACh) linked by their acetyl groups.

  5. Drug

    Imipramine

    go.drugbank.com/drugs/DB00458
    ApprovedInvestigational

    In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, imipramine exerts a positive effect on mood.

  6. Drug

    Lansoprazole

    go.drugbank.com/drugs/DB00448
    ApprovedInvestigational

    along with other pathologies caused by excessive acid secretion. … [A177065] It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD)

  7. Drug

    Medrogestone

    go.drugbank.com/drugs/DB09124
    ApprovedWithdrawn

    [A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.[L1118] It was never approved by the FDA.

  8. Drug

    ZD4407

    go.drugbank.com/drugs/DB06539
    Experimental

    It entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003 … The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.

  9. Drug

    PI-0824

    go.drugbank.com/drugs/DB05516
    Investigational

    The goal of this therapy is to reduce the production of antibodies that cause PV blisters by acting only on the disease causing components of the immune system. … It is hoped that use of PI-0824 will reduce or potentially eliminate the need for high dose steroids and drugs that suppress the immune system.

  10. Drug

    Motexafin lutetium

    go.drugbank.com/drugs/DB05296
    Investigational

    Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. Motexafin lutetium is a pentadentate ...